Skip to main content
SpringerLink
Log in

Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Inhibitors of the platelet receptor glycoprotein (GP) IIb–IIIa are a novel and potent class of antithrombotic drugs for the management of patients with non-ST-segment elevation acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). Pharmacodynamic studies with three currently approved agents in this class (abciximab [ReoPro®, Centocor, Inc., Malvern, Pennsylvania, and Eli Lilly & Company, Indianapolis, Indiana]; eptifibatide [INTEGRILIN®, COR Therapeutics, Inc., South San Francisco, California, and Key Pharmaceuticals, Inc., Kenilworth, New Jersey]; and tirofiban HCI [Aggrastat®, Merck & Co., Inc., Whitehouse Station, New Jersey]) all sought to identify dosing regimens that would establish and maintain >80% inhibition of ex vivo platelet aggregation throughout the duration of intravenous infusion. Direct comparison of these prior studies is difficult, however, because the assays used different anticoagulants (sodium citrate [abciximab, tirofiban HCI] or D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone [PPACK] [eptifibatide]) and different concentrations of the platelet agonist adenosine diphosphate (ADP) (5[emsp4 ]μmol [tirofiban HCI] or 20[emsp4 ]μmol [abciximab, eptifibatide]). More recent work has attempted to overcome these limitations by using similar assay conditions for all GP IIb–IIIa inhibitors. These studies have indicated that the concentrations of all three agents required to provide the targeted effect for platelet inhibition are considerably higher in the presence of an anticoagulant that does not chelate calcium ions (e.g., heparin or PPACK) than in the presence of calcium-chelating anticoagulant (i.e., sodium citrate). Of the three currently approved GP IIb–IIIa inhibitors, eptifibatide is the only agent whose approved dosing is based on an ex vivo platelet aggregation assay that uses such an anticoagulant. Additionally, Kereiakes et al. have recently reported that the high levels of platelet inhibition (>80%), using PPACK as an anticoagulant and ADP (20[emsp4 ]μmol) as an agonist, are more consistently achieved with the approved dosing regimen of eptifibatide. The antiplatelet effect of abciximab showed more interpatient variability, whereas the median inhibition of ex vivo platelet aggregation with the approved dosing regimen for tirofiban HCl was <80% at almost all time points during drug infusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mizuno K, Satomura K, Miyamoto A, et al. Angio-scopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992;326:287–291.

    Google Scholar 

  2. Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med 1996;156:1382–1394.

    Google Scholar 

  3. Almony GT, Lefkovits J, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 1996;19:357–365.

    Google Scholar 

  4. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980;255:154–161.

    Google Scholar 

  5. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988;71:831–843.

    Google Scholar 

  6. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907–914.

    Google Scholar 

  7. Jennings LK, Phillips DR. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem 1982;257:10,458–10,466.

    Google Scholar 

  8. Rivas GA, Gonzalez-Rodriguez J. Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins. Effects of lipids and temperature. Biochem J 1991;276:35–40.

    Google Scholar 

  9. Fujimura K, Phillips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem 1983;258:10,247–10,252.

    Google Scholar 

  10. Johnston GI, Heptinstall S. Identity of saturable calcium-binding sites on blood platelets and their involvement in platelet aggregation. Thromb Haemost 1988;59:54–61.

    Google Scholar 

  11. Fitzgerald LA, Phillips DR. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem 1985;260:11,366–11,374.

    Google Scholar 

  12. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11–25.

    Google Scholar 

  13. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In Fozzard HA, Faber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System: Scientific Foundations, 2nd ed. New York: Raven Press, 1992:219–273.

    Google Scholar 

  14. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553–1559.

    Google Scholar 

  15. Legrand C, Dubernard V, Nurden AT. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood 1989;73:1226–1234.

    Google Scholar 

  16. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(suppl 4A):11B-20B.

    Google Scholar 

  17. Holmbäck K, Danton MJ, Suh TT, Daugherty CC, Degen JL. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin α IIb β 3. EMBO J 1996;15:5760–5771.

    Google Scholar 

  18. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986;44:517–518.

    Google Scholar 

  19. D'Souza SE, Ginsberg MH, Plow EF. Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 1991;16:246–250.

    Google Scholar 

  20. Yamada T, Matsushima M, Inaka K, et al. Structural and functional analyses of the Arg-Gly-Asp sequence introduced into human lysozyme. J Biol Chem 1993;268:10,588–10,592.

    Google Scholar 

  21. Plow EF, Marguerie G, Ginsberg M. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 1987;36:4035–4040.

    Google Scholar 

  22. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990;75:1383–1395.

    Google Scholar 

  23. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33–42.

    Google Scholar 

  24. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956–961.

    Google Scholar 

  25. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689–1696.

    Google Scholar 

  26. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87–92.

    Google Scholar 

  27. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037–2044.

    Google Scholar 

  28. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325–338.

    Google Scholar 

  29. Jordan RE, Wagner CL, Mascelli MA, et al. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In Horton MA, ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, Florida: CRC Press, 1996:281–305.

    Google Scholar 

  30. Ellis SG, Tcheng JE, Navetta FI, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Art Dis 1993;4:167–175.

    Google Scholar 

  31. Knight DM, Wagner C, Jordan R, et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995;32:1271–1281.

    Google Scholar 

  32. Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994;48:583–598.

    Google Scholar 

  33. Tcheng JE, Kereiakes DJ, Braden GA, et al. Read-ministration of abciximab: interim report of the ReoPro readministration registry. Am Heart J 1999:138(1 Pt 2):S33–S38.

    Google Scholar 

  34. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665–1671.

    Google Scholar 

  35. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757–1764.

    Google Scholar 

  36. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680–1688.

    Google Scholar 

  37. Gammie JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465–469.

    Google Scholar 

  38. Kereiakes DJ. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery. Am J Cardiol 1998;81:373–374.

    Google Scholar 

  39. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and α v β 33 integrins. Circulation 1998:98:1085–1091.

    Google Scholar 

  40. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528–535.

    Google Scholar 

  41. Scarborough RM, Rose JW, Hsu MA, et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991;266:9359–9362.

    Google Scholar 

  42. Scarborough RM, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993;268:1058–1065.

    Google Scholar 

  43. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222–1227.

    Google Scholar 

  44. COR Therapeutics, Inc. INTEGRILIN® (eptifibatide) Injection. Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company, Inc., 2001:1106–1110.

    Google Scholar 

  45. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIA receptor. In Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: Marcel Dekker, 1997:355–365.

    Google Scholar 

  46. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536–542.

    Google Scholar 

  47. Merck & Co., Inc. Aggrastat® (tirofiban HCl injection). Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company, Inc., 2001:1868–1872.

    Google Scholar 

  48. Bernardi MM, Califf RM, Kleiman N, Ellis SG, Topol EJ. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group. Am J Cardiol 1993;72:1121–1125.

    Google Scholar 

  49. Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989;113:1219–1224.

    Google Scholar 

  50. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488–1494.

    Google Scholar 

  51. Kleiman NS. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists. Coron Artery Dis 1998;9:603–616.

    Google Scholar 

  52. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988;77:670–677.

    Google Scholar 

  53. Steinhubl SR. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study. J Thromb Thrombolysis 2000;9:199–205.

    Google Scholar 

  54. Tcheng JE, Thel MC, Jennings L, et al. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose INTEGRILINTM in coronary intervention. Results of the PRIDE study. Eur Heart J 1997;18(suppl):624. Abstract.

    Google Scholar 

  55. Collen D, Lu HR, Stassen JM, et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994;71:95–102.

    Google Scholar 

  56. Theroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian lamifiban study. Circulation 1996;94:899–905.

    Google Scholar 

  57. Bell DN, Spain S, Goldsmith HL. Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990;58:47–60.

    Google Scholar 

  58. D'Souza SE, Haas TA, Piotrowicz RS, et al. Ligand and cation binding are dual functions of a discrete segment of the integrin β 3 subunit: cation displacement is involved in ligand binding. Cell 1994;79:659–667.

    Google Scholar 

  59. The PURSUIT Trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436–443.

    Google Scholar 

  60. Choo J, Gretler DD, Gold HK. Platelet aggregation inhibition with single and double bolus regimens of eptifibatide (Integrilin). Am J Cardiol 2000;86(suppl 8A):71i. Abstract.

    Google Scholar 

  61. Nannizzi-Alaimo L, Rychel AL, Teng W, et al. Effect of anticoagulation and platelet agonist concentration on the inhibitory activities of GPIIb-IIIa antagonists. Circulation 1999;100(suppl):1–710. Abstract.

    Google Scholar 

  62. Kukielka GL, Kereiakes DJ, Lorenz T, et al. Differential effects of citrate versus PPACK anticoagulants: implications for comparing glycoprotein IIb/IIIa inhibitors. Am J Cardiol 2000;86(suppl 8A):69i-70i. Abstract.

    Google Scholar 

  63. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999;84:391–395.

    Google Scholar 

  64. Coughlin SR. Molecular mechanisms of thrombin signaling. Semin Hematol 1994;31:270–277.

    Google Scholar 

  65. Scarborough RM, Naughton MA, Teng W, et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 1992;267:13,146–13,149.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Victorian Heart Centre, Epsworth Hospital, Consulting Rooms, Richmond, Australia

    George Proimos

Authors
  1. George Proimos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Proimos, G. Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors. J Thromb Thrombolysis 11, 99–110 (2001). https://doi.org/10.1023/A:1011216414539

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011216414539

Search

Navigation